Next Article in Journal
Kidney Ischemia-Reperfusion Decreases Hydrogen Sulfide and Increases Oxidative Stress in the Heart
Next Article in Special Issue
Identification and Validation of Carbonic Anhydrase II as the First Target of the Anti-Inflammatory Drug Actarit
Previous Article in Journal
Trypanosoma cruzi Presenilin-Like Transmembrane Aspartyl Protease: Characterization and Cellular Localization
Previous Article in Special Issue
DMARDs–Gut Microbiota Feedback: Implications in the Response to Therapy
Open AccessArticle

Rheumatoid Arthritis: Applicability of Ready-to-Use Human Cartilaginous Cells for Screening of Compounds with TNF-Alpha Inhibitory Activity

Institute of Experimental Medicine and Biotechnology, Samara State Medical University, Chapaevskaya St., 89, 443099 Samara, Russia
*
Author to whom correspondence should be addressed.
Biomolecules 2020, 10(11), 1563; https://doi.org/10.3390/biom10111563
Received: 2 October 2020 / Revised: 29 October 2020 / Accepted: 10 November 2020 / Published: 17 November 2020
(This article belongs to the Special Issue Pathogenesis of Arthritis)
In the context of modern drug discovery, there is an obvious advantage to designing phenotypic bioassays based on human disease-relevant cells that express disease-relevant markers. The specific aim of the study was to develop a convenient and reliable method for screening compounds with Tumor Necrosis Factor-alpha (TNF-α) inhibitory activity. This assay was developed using cryopreserved ready-to-use cartilage-derived cells isolated from juvenile donors diagnosed with polydactyly. It has been demonstrated that all donor (10 donors) cells were able to respond to TNF-α treatment by increased secretion of pro-inflammatory cytokine IL-6 into subcultural medium. Inhibition of TNF-α using commercially available TNF-α inhibitor etanercept resulted in a dose-dependent decrease in IL-6 production which was measured by Enzyme-Linked Immunosorbent Assay (ELISA). TNF-α dependent IL-6 production was detected in the cells after both their prolonged cultivation in vitro (≥20 passages) and cryopreservation. This phenotypic bioassay based on ready-to-use primary human cells was developed for detection of novel TNF-α inhibitory compounds and profiling of biosimilar drugs. View Full-Text
Keywords: rheumatoid arthritis; cartilage; tumor necrosis factor assay; primary cell culture; interleukin-6 rheumatoid arthritis; cartilage; tumor necrosis factor assay; primary cell culture; interleukin-6
Show Figures

Figure 1

MDPI and ACS Style

Volova, L.T.; Pugachev, E.I.; Rossinskaya, V.V.; Boltovskaya, V.V.; Dolgushkin, D.A.; Ossina, N. Rheumatoid Arthritis: Applicability of Ready-to-Use Human Cartilaginous Cells for Screening of Compounds with TNF-Alpha Inhibitory Activity. Biomolecules 2020, 10, 1563. https://doi.org/10.3390/biom10111563

AMA Style

Volova LT, Pugachev EI, Rossinskaya VV, Boltovskaya VV, Dolgushkin DA, Ossina N. Rheumatoid Arthritis: Applicability of Ready-to-Use Human Cartilaginous Cells for Screening of Compounds with TNF-Alpha Inhibitory Activity. Biomolecules. 2020; 10(11):1563. https://doi.org/10.3390/biom10111563

Chicago/Turabian Style

Volova, Larissa T.; Pugachev, Evgeniy I.; Rossinskaya, Victoria V.; Boltovskaya, Violetta V.; Dolgushkin, Dmitry A.; Ossina, Natalya. 2020. "Rheumatoid Arthritis: Applicability of Ready-to-Use Human Cartilaginous Cells for Screening of Compounds with TNF-Alpha Inhibitory Activity" Biomolecules 10, no. 11: 1563. https://doi.org/10.3390/biom10111563

Find Other Styles
Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.

Article Access Map by Country/Region

1
Search more from Scilit
 
Search
Back to TopTop